Cargando…

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19

Detalles Bibliográficos
Autores principales:	Mourad, Jean-Jacques, Levy, Bernard I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104419/ https://www.ncbi.nlm.nih.gov/pubmed/32231328 http://dx.doi.org/10.1038/s41569-020-0368-x

Ejemplares similares

Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
por: Zheng, Ying-Ying, et al.
Publicado: (2020)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
por: Milne, Stephen, et al.
Publicado: (2020)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
por: Michaud, Veronique, et al.
Publicado: (2020)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

ACE2 Elevation in Severe COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2021)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

Reply to: RAAS inhibitors in COVID-19: not all are created equal!
por: Gonçalves, Jorge, et al.
Publicado: (2023)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?
por: Silhol, François, et al.
Publicado: (2020)

Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?
por: Garg, Mayur, et al.
Publicado: (2020)

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
por: Wang, James Jiqi, et al.
Publicado: (2020)

A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection
por: Krishna, Bhuvana
Publicado: (2021)

New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis
por: Hou, Yuan, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

COVID-19 and ACE2 in the Liver and Gastrointestinal Tract: Putative Biological Explanations of Sexual Dimorphism
por: Pirola, Carlos J., et al.
Publicado: (2020)

Rhinovirus Infections in Individuals with Asthma Increase ACE2 Expression and Cytokine Pathways Implicated in COVID-19
por: Chang, Eugene H., et al.
Publicado: (2020)

COVID-19 and the RAAS—a potential role for angiotensin II?
por: Busse, Laurence W., et al.
Publicado: (2020)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein–ACE2 interaction
por: Yuan, MengYa, et al.
Publicado: (2021)

The COVID-19 syndemic is not global: context matters
por: Mendenhall, Emily
Publicado: (2020)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Human pluripotent stem cell-derived functional sympathetic neurons express ACE2 and RAAS components: a framework for studying the effect of COVID-19 on sympathetic responsiveness
por: Wu, Hsueh-Fu, et al.
Publicado: (2022)

ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients
por: Ramos, Simone Gusmão, et al.
Publicado: (2021)

Protective effects of eosinophils against COVID-19: More than an ACE(2) in the hole?
por: Drake, Matthew G., et al.
Publicado: (2021)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID‐19
por: Gupta, Neelesh, et al.
Publicado: (2020)

Neuraxial anaesthesia in the context of bacterial meningitis and COVID-19
por: Allen, Matthew B., et al.
Publicado: (2020)

Maternal psychological health in context with COVID-19 pandemic
por: Panda, Soumya Ranjan
Publicado: (2021)

The vaccinated proportion of people with COVID-19 needs context
por: Egger, Sam, et al.
Publicado: (2022)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis
por: Pirola, Carlos J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c2pvda806d8vb58k5hidrrpq6p